MRPL17

MRPL17 (bL17m/mL46) is a structural component of the mitochondrial ribosome large subunit that supports mitochondrial respiratory function and energetic output (PMID:28931599, PMID:41422086). It assembles into a defined subcomplex at the mitospecific central protuberance of the mitoribosome together with mL38, uL5, bL27, bL31, and mL40 (PMID:28931599). Functionally, MRPL17 is required to sustain oxidative phosphorylation: its loss reduces oxygen consumption, Complex I activity, and ATP production, with COX8A acting as a downstream effector mediating its pro-respiratory and pro-cancerous effects (PMID:41422086). Consistent with this energetic role, MRPL17 acts as a regulator of respiratory chain function downstream of FABP5, and its overexpression rescues the mitochondrial dysfunction and apoptosis caused by FABP5 deficiency (PMID:40480484). Beyond these roles in mitoribosome assembly and respiratory support, no further mechanistic detail has been characterized in the available corpus.

1. 2017 Medium

   Established that MRPL17/mL46 is not a free protein but an integral component of a defined mitoribosomal large-subunit subcomplex, localizing its function to the central protuberance of the mitoribosome.

   Evidence Co-isolation and subcomplex purification of yeast mitoribosomal components

   PMID:28931599

   Open questions at the time

   • Single-lab co-isolation in yeast ortholog; assembly order and stoichiometry not resolved
   • No direct structural model of the human subcomplex
   • Role in human mitoribosome assembly not demonstrated
2. 2025 Medium

   Demonstrated that MRPL17 is functionally required for respiratory chain output, linking its loss to reduced Complex I activity and ATP production, and identified COX8A as a direct downstream effector.

   Evidence siRNA/CRISPR knockout in NSCLC cell lines with oxygen consumption, Complex I activity, ATP assays, xenografts, and COX8A target confirmation

   PMID:41422086

   Open questions at the time

   • Mechanism by which MRPL17 controls COX8A is not defined at the molecular level
   • Whether the respiratory defect reflects a general mitoribosome assembly failure versus a specific role is unresolved
   • Findings restricted to NSCLC context
3. 2025 Medium

   Positioned MRPL17 as a downstream regulator of respiratory chain enzyme synthesis whose restoration can rescue mitochondrial dysfunction, showing its activity is rate-limiting for mitochondrial integrity in another cell type.

   Evidence siRNA FABP5 knockdown with RNA-seq, MRPL17 overexpression rescue, membrane potential, ATP, and apoptosis readouts in decidual stromal cells

   PMID:40480484

   Open questions at the time

   • How FABP5 regulates MRPL17 expression mechanistically is unknown
   • Direct biochemical link between MRPL17 level and enzyme complex synthesis not shown
   • Single-lab rescue experiment
4. 2026 Low

   Associated MRPL17 protein dysregulation with a mitochondrial function module in a disease model, extending its relevance to in vivo pathophysiology without defining mechanism.

   Evidence Quantitative proteomics of prefrontal cortex with PRM and Western blot validation in a chronic social defeat stress mouse model

   PMID:41765126

   Open questions at the time

   • Correlative protein-level dysregulation only; no mechanistic insight into MRPL17 function
   • Causal contribution to the phenotype not tested
   • Single model, single lab

• The biochemical mechanism by which MRPL17 incorporation into the mitoribosome controls respiratory chain assembly and COX8A levels remains undefined.
• No structural model of the human MRPL17-containing subcomplex
• Mechanism linking mitoribosome assembly to COX8A regulation unknown
• No reconstitution of MRPL17 function in translation